Phase II results of an intraocular steroid delivery system for cataract surgery

Chang, David F.; García, Iván Hernández; Hunkeler, John D.; Minas, T.

doi:10.1016/s0161-6420(99)90262-2

Cited by 49 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the outcome of the study demonstrated no significant differences in complications or efficacy between the anterior chamber or sulcus implantations. [150][151] In another study, Kodama et al investigated anti-inflammatory activity of Surodex in 2 experimental intraocular inflammation model; experimental autoimmune uveoretinitis and endotoxin-induced uveitis. 152 Treatment with Surodex exhibited significantly reduced inflammation in both animal models.…”

mentioning

confidence: 99%

Novel Strategies for Anterior Segment Ocular Drug Delivery

Cholkar

Patel

Vadlapudi

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

151

107

View full text Add to dashboard Cite

Research advancements in pharmaceutical sciences have led to the development of new strategies in drug delivery to anterior segment. Designing a new delivery system that can efficiently target the diseased anterior ocular tissue, generate high drug levels, and maintain prolonged and effective concentrations with no or minimal side effects is the major focus of current research. Drug delivery by traditional method of administration via topical dosing is impeded by ocular static and dynamic barriers. Various products have been introduced into the market that prolong drug retention in the precorneal pocket and to improve bioavailability. However, there is a need of a delivery system that can provide controlled release to treat chronic ocular diseases with a reduced dosing frequency without causing any visual disturbances. This review provides an overview of anterior ocular barriers along with strategies to overcome these ocular barriers and deliver therapeutic agents to the affected anterior ocular tissue with a special emphasis on nanotechnology-based drug delivery approaches.

show abstract

mentioning

confidence: 99%

Novel Strategies for Anterior Segment Ocular Drug Delivery

Cholkar

Patel

Vadlapudi

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

151

107

View full text Add to dashboard Cite

show abstract

“…It contains 60 µg dexamethasone incorporated into a polymer matrix of poly(lactic-glycolic acid), and achieves higher intraocular drug levels than conventional dexamethasone eye drops [46]. Randomised controlled trials found Surodex to be as effective as 0.1% dexamethasone eye drops in the control of postcataract surgery inflammation [46,47,48] but, as it only lasts for 7 days, its usefulness does not extend beyond postoperative uveitis.…”

Section: Surodexmentioning

confidence: 99%

New Developments in Corticosteroid Therapy for Uveitis

et al. 2010

View full text Add to dashboard Cite

Corticosteroids remain the mainstay of the management of patients with uveitis. Topical corticosteroids are effective in the control of anterior uveitis, but vary in strength, ocular penetration and side effect profile. Systemic corticosteroids are widely used for the management of posterior segment inflammation which requires treatment, particularly when it is associated with systemic disease or when bilateral ocular disease is present. However, when ocular inflammation is unilateral, or is active in one eye only, local therapy has considerable advantages, and periocular injections of corticosteroid are a useful alternative to systemic medication and are very effective in controlling mild or moderate intraocular inflammation. More recently, the injection of intraocular corticosteroids such as triamcinolone have been found to be effective in reducing macular oedema and improving vision in uveitic eyes which have proved refractory to systemic or periocular corticosteroids. The effect is usually transient, lasting around 3 months, but can be repeated although the side effects of cataract and raised intraocular pressure are increased in frequency with intraocular versus periocular corticosteroid injections. This has led to the development of new intraocular corticosteroid devices which are designed to deliver sustained-release drugs and obviate the need for systemic immunosuppressive treatment. The first such implant was Retisert, which is surgically implanted (in the operating theatre) and is designed to release fluocinolone over a period of about 30 months. More recently, Ozurdex, a ‘bioerodible’ dexamethasone implant which can be inserted in an office setting, has completed phase III clinical trials in patients with intermediate and posterior uveitis. This implant lasts approximately 6 months, and has been found to be effective with a much better side effect profile than Retisert or intravitreal triamcinolone injection, at least for one injection.

show abstract

“…The implant showed a constant level of fluorometholone in the aqueous humor for 1 month and was well tolerated in the rabbit eyes. Recently, randomized clinical trials of a new dexamethasone delivery system (Surodex ® ) for treatment of postcataract surgery inflammation have been done [49, 50]. Surodex (Oculex Pharmaceuticals, Inc.) is a PLGA rod (1.0 mm in length and 0.5 mm in diameter) containing 60 µg of dexamethasone, which releases the drug over a period of approximately 7–10 days.…”

Section: Drug Delivery Systems With Pla and Plgamentioning

confidence: 99%

“…Surodex (Oculex Pharmaceuticals, Inc.) is a PLGA rod (1.0 mm in length and 0.5 mm in diameter) containing 60 µg of dexamethasone, which releases the drug over a period of approximately 7–10 days. Multicenter, randomized, double-masked, parallel group study revealed that Surodex was safe and effective in suppressing postoperative inflammation after uncomplicated cataract surgery [50]. …”

Section: Drug Delivery Systems With Pla and Plgamentioning

confidence: 99%

Biodegradable Polymers for Ocular Drug Delivery

2001

View full text Add to dashboard Cite

A variety of ocular drug delivery systems, including a controlled release of the drug, drug targeting, and penetration enhancement of the drug, have been investigated. Biodegradable polymers have been widely used as the drug carrier for controlled-release systems. Biodegradable polymers release the drug as they themselves degrade and are finally absorbed within the body. Several ocular drug delivery systems using different kinds of biodegradable polymers have been studied. In this article, we describe the fundamental mechanisms of drug delivery systems, polymer erosion and drug release, and then review those systems using the most popular biodegradable polymers, poly(lactic acid) and poly(lactic-glycolic acid).

show abstract

Phase II results of an intraocular steroid delivery system for cataract surgery

Cited by 49 publications

References 12 publications

Novel Strategies for Anterior Segment Ocular Drug Delivery

Novel Strategies for Anterior Segment Ocular Drug Delivery

New Developments in Corticosteroid Therapy for Uveitis

Biodegradable Polymers for Ocular Drug Delivery

Contact Info

Product

Resources

About